Therapeutic Action
Antipsychotic
Source page 161
Loading InternPractice…
Individual generic drug information
Extracted information for HALOPERIDOL only.
Antipsychotic
Source page 161
Acute confusional state (delirium) and acute alcohol intoxication Acute or chronic psychosis Acute manic episode Agitation or aggressive behaviour in patients with acute or chronic psychosis, in combination with promethazine
Source page 161
Extracted information for HALOPERIDOL only.
Do not administer to patients with cardiac disorders (heart failure, recent myocardial infarction, conduction disorders, bradycardia, etc.), dementia (e.g. Alzheimer's disease), Parkinson's disease and history of neuroleptic malignant syndrome. Administer with caution and carefully monitor use in older patients and patients with hypokalaemia, hypotension, hyperthyroidism, renal or hepatic impairment, history of seizures. May cause: drowsiness (caution when driving/operating machinery), extrapyramidal symptoms, early or tardive dyskinesia, anticholinergic effects (constipation, dry mouth), hyperprolactinaemia, weight gain, sexual dysfunction, QT-prolongation, ventricular arrhythmia, orthostatic hypotension; neuroleptic malignant syndrome (unexplained hyperthermia with neuromuscular disorders), rare but requiring immediate treatment discontinuation. In case of extrapyramidal symptoms, try reducing the dose of haloperidol or, if the extrapyramidal symptoms are severe, add biperiden or trihexyphenidyl. Avoid or monitor combination with: central nervous system depressants (opioid analgesics, sedatives, H1 antihistamines, etc.); fluoxetine, paroxetine, sertraline, ritonavir (increased plasma concentrations of haloperidol); carbamazepine, rifampicin, phenobarbital, phenytoin (decreased plasma concentrations of haloperidol); antihypertensive drugs (risk of hypotension); drugs that prolong the QT interval (amiodarone, chloroquine, erythromycin, fluconazole, mefloquine, pentamidine, quinine, etc.). Avoid alcohol during treatment (increased risk of adverse effects). Pregnancy: re-evaluate whether the treatment is still necessary; if it is continued, use the lowest effective dose. Observe the neonate the first few days (risk of agitation, tremors, hypertonia/hypotonia, respiratory difficulties, sleeping disorders, etc.) if the mother was under rd treatment in the 3 trimester. Breast-feeding: if absolutely necessary, do not exceed 10 mg daily.
Source page 162
Extracted information for HALOPERIDOL only.
0.5 mg, 1.5 mg and 5 mg tablets 2 mg/ml oral solution with pipette graduated in mg
Source page 161
Acute confusional state (delirium) and acute alcohol intoxication Adult: 0.5 to 1 mg 2 times daily Acute or chronic psychosis Adult: 0.5 to 1 mg 2 times daily. Gradually increase up to 10 mg daily if necessary (max. 15 mg daily). Acute manic episode Adult: 5 mg once daily. Gradually increase up to 10 mg daily if necessary (max. 15 mg daily). Agitation or aggressive behaviour in patients with acute or chronic psychosis, with promethazine Adult: 5 mg, to be repeated after 60 minutes if necessary Reduce the dose by half in older patients (max. 5 mg daily). Use the lowest effective dose, especially in the event of prolonged treatment.
Source page 161
Delirium and acute alcohol intoxication: as short as possible (max. 7 days) Acute psychosis: at least 3 months Chronic psychosis: at least one year Manic episode: 8 weeks after remission of symptoms Discontinue treatment gradually (over 4 weeks). If signs of relapse occur, increase the dose then decrease it more gradually.
Source page 162
Extracted information for HALOPERIDOL only.
– – Below 25 °C
Source page 162
Filter the extracted dose blocks for this individual drug.
0.5 to 1 mg 2 times daily
Candidate age grouping · source page 161
0.5 to 1 mg 2 times daily. Gradually increase up to 10 mg daily if necessary (max. 15 mg daily).
Candidate age grouping · source page 161
5 mg once daily. Gradually increase up to 10 mg daily if necessary (max. 15 mg daily).
Candidate age grouping · source page 161
5 mg, to be repeated after 60 minutes if necessary
Candidate age grouping · source page 161